摘要
目的 观察奥希替尼联合化疗治疗晚期肺腺癌的效果.方法 选取2021年7月～2023年8月收治的80例晚期肺腺癌患者,按简单随机数字表法分为对照组(n=40)和观察组(n=40).对照组采用培美曲塞联合顺铂化疗治疗,观察组加用奥希替尼.比较两组患者的临床疗效、肿瘤标志物水平、血管生长因子、不良反应及生活质量.结果 观察组的总有效率及Karnofsky评分高于对照组(P＜0.05);治疗后观察组的CEA[(8.53±1.37)ng/ml]、CA125[(46.71±5.82)U/ml]、CYFRA21-1[(11.06±2.08)ng/ml]、CA199[(45.83±9.26)U/ml]及bFGF[(149.85±18.69)pg/ml]、MMP-9[(1 012.47±85.47)ng/ml]、VEGF[(230.41±41.87)pg/ml]水平均低于对照组[(12.73±2.45)ng/ml、(58.47±6.59)U/ml、(14.76±1.85)ng/ml、(51.72±9.58)U/ml、(176.49±19.54)pg/ml、(1 461.37±96.54)ng/ml、(271.47±48.35)pg/ml](P＜0.05);观察组不良反应发生率32.50%和对照组的25.00%对比,差异无统计学意义(P＞0.05).结论 对于晚期肺腺癌患者,在化疗的基础上采用奥希替尼治疗具有明显的效果,可降低患者的肿瘤标志物和血管生长因子水平,提升生存质量,且具有一定的安全性.
Abstract
Objective To observe the effect of osimertinib combined with chemotherapy in the treatment of advanced lung adenocarcinoma.Methods A total of 80 patients with advanced lung adenocarcinoma admitted from July 2021 to August 2023 were randomly divided into the control group(n=40)and the observation group(n=40).The control group was treated with pemetrexed combined with cisplatin.The observation group was given osimertinib.The clinical efficacy,tumor marker levels,vascular growth factors,adverse reactions and quality of life were compared between the two groups.Results The total effective rate and Karnofsky score in the observation group were higher than those in the control group(P＜0.05).After treatment,the observation group CEA[(8.53±1.37)ng/ml],CA125[(46.71±5.82)U/ml],CYFRA21-1[(11.06±2.08)ng/ml],CA199[(45.83±9.26)U/ml],bFGF[(149.85±18.69)pg/ml],MMP-9[(1 012.47±85.47)ng/ml],VEGF[(230.41±41.87)pg/ml]were lower than those in the control group[(12.73±2.45)ng/ml,(58.47±6.59)U/ml,(14.76±1.85)ng/ml,(51.72±9.58)ng/ml,(176.49±19.54)pg/ml,(1 461.37±96.54)ng/ml,(271.47±48.35)pg/ml](P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group(32.50%)and the control group(25.00%)(P＞0.05).Conclusion For patients with advanced lung adenocarcinoma,the use of on the basis of chemotherapy has obvious effects,can reduce the level of tumor markers and vascular growth factor,improve the quality of life of patients,and has a certain safety.
维普
万方数据